Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Aug 26, 2023 12:08pm
154 Views
Post# 35606716

RE:SEC COMPLAINT

RE:SEC COMPLAINT PMN on Nasdaq YTD Jan 3rd to July 16th, 403,308 shares traded. July 17th, 13,976,020 traded. That day traded 35 times more than all YTD. This will flag big time with the SEC and the following days.
Last placement October 12,22. Chairman of the Board Eugene Williams quote "Promis anticipates submission of an IND for PMN 310 by year-end 2022'.

Do people really believe Gail Farfel or Eugene Williams based on their past history of statements and actions?

Investors that do not get on board and question the INTEGRITY and ETHICS of this Board and Management better take off the rose colored glasses. Report to the SEC  and other outlets, let them investigate and clear the air.

<< Previous
Bullboard Posts
Next >>